The aim of the study was to investigate the in vitro and in vivo pharmacological profile of
cebranopadol, a novel agonist for opioid and nociceptin/orphanin FQ (N/OFQ) receptors …

A major limitation in the study of the mu-delta opioid receptor heterodimer (MDOR) is that
few selective pharmacological tools exist and no heteromer-selective antagonists. We thus …

Endogenous opioid peptides and prescription opioid drugs modulate pain, anxiety and
stress by activating four opioid receptors, namely μ (mu, MOP), δ (delta, DOP), κ (kappa …

Mu opioid receptor (MOR)-targeting analgesics are efficacious pain treatments, but
notorious for their abuse potential. In preclinical animal models, coadministration of …

The 17-amino acid neuropeptide nociceptin/Orphanin FQ (N/OFQ) was recently identified as
the endogenous ligand for the opioid receptor-like (ORL1) receptor, a fourth member of the …

We report the discovery of spiro [cyclohexane-pyrano [3, 4-b] indole]-amines, as functional
nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonists with strong efficacy in …

Nociceptin (orphanin FQ) is the recently discovered peptide agonist for the orphan receptor
opioid receptor-like 1 (ORL1). Despite the high sequence homology between ORL1 and the …

Preclinical evidence has highlighted the importance of the m-opioid peptide (MOP) receptor
on primary afferents for both the analgesic actions of MOP receptor agonists, as well as the …

Nociceptin/orphanin FQ (N/OFQ) was recently identified as the endogenous ligand for the
opioid-receptor like (ORL1) receptor. Although the ORL1 receptor shows sequence …

Opioids targeting mu; μ (MOP) receptors produce analgesia in the peri-operative period and
palliative care. They also produce side effects including respiratory depression …